Nektar TherapeuticsNektar TherapeuticsNektar Therapeutics

Nektar Therapeutics

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪322.26 M‬USD
−0.92USD
‪−276.06 M‬USD
‪90.12 M‬USD
‪178.28 M‬
Beta (1Y)
1.17

About Nektar Therapeutics

CEO
Howard W. Robin
Headquarters
San Francisco
Website
Employees (FY)
137
Founded
1990
FIGI
BBG000BHCYJ1
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of NKTR is 1.75 USD — it has decreased by 0.28% in the past 24 hours. Watch Nektar Therapeutics stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Nektar Therapeutics stocks are traded under the ticker NKTR.
NKTR stock has fallen by 5.91% compared to the previous week, the month change is a 31.58% rise, over the last year Nektar Therapeutics has showed a 151.08% increase.
We've gathered analysts' opinions on Nektar Therapeutics future price: according to them, NKTR price has a max estimate of 1.60 USD and a min estimate of 1.60 USD. Watch NKTR chart and read a more detailed Nektar Therapeutics stock forecast: see what analysts think of Nektar Therapeutics and suggest that you do with its stocks.
NKTR reached its all-time high on Mar 12, 2018 with the price of 111.36 USD, and its all-time low was 0.41 USD and was reached on Nov 13, 2023. View more price dynamics on NKTR chart.
See other stocks reaching their highest and lowest prices.
NKTR stock is 5.36% volatile and has beta coefficient of 1.17. Track Nektar Therapeutics stock price on the chart and check out the list of the most volatile stocks — is Nektar Therapeutics there?
Today Nektar Therapeutics has the market capitalization of ‪322.26 M‬, it has increased by 7.53% over the last week.
Yes, you can track Nektar Therapeutics financials in yearly and quarterly reports right on TradingView.
Nektar Therapeutics is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
NKTR earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.19 USD resulting in a 0% surprise. The estimated earnings for the next quarter are −0.21 USD per share. See more details about Nektar Therapeutics earnings.
Nektar Therapeutics revenue for the last quarter amounts to ‪21.64 M‬ USD despite the estimated figure of ‪15.34 M‬ USD. In the next quarter revenue is expected to reach ‪20.51 M‬ USD.
NKTR net income for the last quarter is ‪−36.80 M‬ USD, while the quarter before that showed ‪−42.08 M‬ USD of net income which accounts for 12.54% change. Track more Nektar Therapeutics financial stats to get the full picture.
No, NKTR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 20, 2024, the company has 137.00 employees. See our rating of the largest employees — is Nektar Therapeutics on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Nektar Therapeutics EBITDA is ‪−125.54 M‬ USD, and current EBITDA margin is −143.82%. See more stats in Nektar Therapeutics financial statements.
Like other stocks, NKTR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Nektar Therapeutics stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Nektar Therapeutics technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Nektar Therapeutics stock shows the neutral signal. See more of Nektar Therapeutics technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.